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ABSTRACT
There is mounting evidence of impacts of single base substitutions in both somatic and
inherited genetic diseases. However, the occurrence of single base mutations in the
germline and gametes has previously only been by conjecture and assumption. There is a
need for understanding the risk of offspring inheriting small intragenic mutations, the
frequencies at which these mutations are present in germ cells, and the impact that these
inherited mutations may have son the predisposition to somatic disease during one’s
lifetime. The present study attempts to establish baselines of mutational frequencies in
two well characterized genes in human tissues, and demonstrate the prevalence of
mutations in two genes, Kristen-ras (KRAS) and TP53 in direct analysis of semen
specimens. These two genes play important roles in human disease. Eleven normal
human male volunteers’ semen specimens were tested for single base substitutions (SBS).
A detection sensitivity of one mutant cell in 106 wild type cells was achieved with the aid
of an ultra-sensitive detection method, which utilizes the combined power of the
polymerase chain reaction, restriction endonuclease, and ligase chain reaction techniques.
The first base of the TP53 gene codon 248, 282, 273 and the second base of codon 273
and the first base of the Kristen-Ras (KRAS) gene codon 12 were studied. The observed
mutation prevalence was significantly higher in the first base of the codon 248 of the
TP53 gene compared to the first base of codon 273 or the first base of codon 282, both
(both P< 0.006). Similarly, there was a significant difference between the prevalence of
the first base of codon 12 of the KRAS gene and the first base of codon 273, or the first
base of codon 282 (both P< 0.04). Interestingly, the SBS mutation prevalence was nearly
the same in the first base of codon 12 KRAS gene and the first base in codon 248 of the
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TP53 gene (P< 0.006). The spectra of base substitution mutations observed in this study
may provide clues to the mutational mechanisms present in human sperm, and may lead
to the improved risk assessment for genetic counseling. These data represent the first
reports of mutational frequencies in the TP53 and KRAS genes in normal human semen
specimens, and demonstrate that single base mutational frequencies for different genes
can be obtained directly from semen samples.
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CHAPTER 1
INTRODUCTION AND REVIEW OF LITERATURE
1.1 Introduction
Despite the advances in molecular biology during the last two decades, such as
the human genome project, sequence data, and microarray technologies, there are still
relatively few studies looking at mutations in human sperm. Microarrays coupled with
automation have resulted in large-scale experiments and the development of extensive
databases to handle the enormous amounts of information. Unfortunately, only limited
data are available for a database in the mutational frequencies unique to human sperm
(Wiederkehr et al., 2004).

Traditionally, obstacles to exploring mutations in sperm

included; the lack of specificity and/or sensitivity when focusing on a single gene or
region within a single gene, and the labor intensive nature of standard techniques, e.g.,
mouse specific locus (Wilson et al., 1999). Direct analysis of sperm has been undertaken
with a number of methods including fluorescence in situ hybridization (Sloter et al.,
2000), hamster-egg method (Brandriff et al., 1990), and flow or laser-scanning cytometry
(Pasteur et al., 1994; Baumgartner et al., 2001; Cordelli et al., 2005). However, these
studies have for the most part, been driven by clinical infertility and the search for gross
chromosomal abnormalities that may be transmitted through gametes (Rudak et al., 1978;
Shelby et al., 1993; Hassold et al., 1996; Rubes et al., 2002; Schmidt et al., 2004).
1.2 Chromosome Aberrations
Chromosomal aberrations are associated with a wide range of defects, genetic
diseases, and mortality (Wyrobek et al., 2000). Chromosomal aberrations have been
estimated to occur in ~ 0.6% of live-born infants (Hassold et al., 1996; Marchetti and
Wyrobek, 2005). However, the frequency of sperm harboring chromosomal aberrations
1

may be much higher, since many of these mutations are not compatible with conception,
implantation, embryogenesis and/or life. Based on clinically recognized conceptions
(i.e., pregnancies), approximately 85% make it to birth, with miscarriage occurring in 1015% (Lauritsen, 1975; Kalousek et al., 1993; Hassold, 1996). However, Wilcox et al.,
1988, and Tommerup, 1993, propose that 30-50% of all conceptions do not lead to
recognized pregnancies. A significant proportion of the conceptions that do not survive
to live offspring may be the result of genetic errors, so that only about 50% of all
conceptions (recognized and unrecognized) survive to birth (Marchetti and Wyrobek,
2005).

Using the human sperm-hamster oocyte fusion system and more recently a

multicolor fluorescence in situ hybridization (FISH) assay, it has been shown that
structural aberrations may be widespread in the sperm of infertile men (Rudak et al.,
1978; Schmidt et al., 2004). Rubes et al., 2002, utilized FISH techniques to examine
multiple semen specimens collected from healthy men over a two year period, and
identified men who consistently produced elevated frequencies of aneuploid sperm.
Rudak et al. 1978, suggest that chromosomal abnormalities occur at a rate of 5-7% in
normal sperm from fertile males, which is consistent with the structural chromosomal
abnormality rate of 5-13% found by Marchetti and Wyrobek, 2005.
With the mounting evidence of the impact of single base substitution in somatic cells and
the potential to cause heritable disease in progeny, there is a need for understanding the
risk of offspring inheriting rare mutations, frequencies at which these mutations are
present in germ cells, and the impact these mutations may have in the susceptibility of
disease.

2

1.3 Single-base Substitution Mutations
The occurrence of constitutional deletions, insertions, and single base-substitution
(SBS) mutations is well known in various genetic diseases (i.e., Sickle-cell anemia,
Retinoblastoma, Neurofibromatosis type 1, Fragile X syndrome, Li-fraumeni syndrome,
etc.)(Table 1). However, the determination of the frequency of sperm harboring these
mutations has been difficult due to technical limitations (sensitivity and/or specificity).
The frequency of SBS has been widely proposed in the literature as an indicator of
somatic disease, heritable predisposition to somatic disease, and/or exposure to one or
more genotoxic agents (Loeb et al., 2003; Wilson et al., 2000; Wilson, 2001). The
transmission of de novo SBS mutations, unlike chromosomal aberrations, generally
results in a viable fetus, but is a major etiological factor in hereditary predisposition to
disease. This is seen most notably in the high penetrance of autosomal dominant diseases
and predisposition to disease caused by SBS mutations such as achondroplasia (FGFR3),
apert syndrome (FGFR2), multiple endocrine neoplasia type 2 (RET), and retinoblastoma
(RB) among others (Table 2).

Traditionally, the reported frequencies of germline

mutations are estimated from the prevalence or incidence of disease in the population.
Orioli et al., 1986, estimated an Achondroplasia mutation rate of 1.72 to 5.57 x 10-5 per
gamete per generation (based on birth prevalence of 0.5 to 1.5/10,000).

Thus far,

Achondroplasia causing mutations appear to be 100% of paternal origin (Tiemann-Boege
et al., 2002) so that this mutation rate corresponds with the reported frequency of 0.5 to
1.5 x 10-5 for FGFR3 G1138A mutants present in human sperm (Tiemann-Boege et al.,
2002). The birth prevalence of Apert syndrome has been reported to be 1.5 x 10-5, which
predicts the same prevalence of the mutation in sperm (Goriely et al., 2003). Dryja et al.,
1997, predicts about 85% of de novo germline mutations occur in the paternally derived
3

allele in Retinoblastoma. De novo mutations are reported to account for 20% to 30% of
the mutations in retinoblastoma and the germ cell mutation rate is estimated to be 9.3 x
10-6 to 10.9 x 10-6 per generation (Fitzgerald et al., 1983). These disease associated
mutation SBS frequencies suggest a sperm SBS mutation frequency of 1 x 10-4 to 1 x 10-5
mutant sperm per total spermatozoa sampled. A germ cell p53 mutation rate of 1 x 10-4
mutant sperm per total spermatozoa sampled, would suggest that disease associated
mutations potentially leading to a disease prevalence of greater than one in one-hundred
thousand for the Li-Fraumeni cancer family syndrome. The actual prevalence of LiFraumeni in the human population is much less than 1 x 10-6 per generation (Bendig et
al., 2004), which suggests either these estimated mutation rates are inaccurate or an
opposing biological selection occurs during the processes of conception to birth.
The research study reported here utilizes direct analyses of human semen samples
to determine the prevalence of mutations in the Kristen-Ras (KRAS) and TP53 genes,
both of which have important roles in human disease (i.e. cancer). The goals of these
experiments are to establish base-lines of mutational frequencies of two well
characterized genes in human sperm. The specific objectives are to determine whether
SBS mutational frequencies in the TP53 and KRAS genes can be obtained from direct
analysis of human semen specimens, and to determine whether or not SBS mutational
frequencies in sperm are similar between activating (KRAS) and de-activating (TP53)
mutations.
1.4 Human TP53 and Kristen-Ras (KRAS) Gene
The tumor suppressor gene TP53 (MIM#191117) encodes a transcription factor with
multiple anti-proliferative functions activated in response to several forms of cellular
stress.
4

Table 1. Examples of genetic diseases caused by insertion and deletion mutations.
expecteda
1.0 x 10-5 b

Disease
Cri du chat

mutation
deletion

prevalence
2 x 10-5

Fragile X

CGG repeats

5 x10-5

FMR 1

2 x 10-4
2 x 10- 4
(live male births)

Factor VIII Soucie et al., 1998
or IX

Hemophilia
X –linked
Hemophilia B

inversion

7.7 x 10-6

3.85 x 10-6 c

Huntington

CAG repeats
to 6 x 10-6

4 x 10-6
to 3 x 10-6 c

Neurofibromatosis
(~90%)

deletion

Retinoblastoma

deletion

“

deletion
(~31%)

Wilms Tumor

deletion

gene
chr-5

Reference(s) __
Overhauser et al.,
1994
Jacobs, 1982

“

Green et al., 1999

2 x 10-6 c

HD

Duyao et al., 1993

2.9 x 10-4

2.5 x 10-4 c

NF1

Lazaro et al., 1996

4.35 x 10-5
to 6.25 x 10-5

1.9 x 10-5 c
to 2.8 x 10-5 c

“

Sippel et al., 1998

1.3 x 10-5 c

“

Lohmann et al.,
1996

5 x 10-4 c

WT1

Olson et al., 1993

“
1 x 10-3
(children)

a

expected frequency in sperm calculated from population prevalence and percent due to a paternal mutation
paternal genome represents ≤ 10% of the mutation incidence
c
assumed ~ 50% mutation from paternal genome
b
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Table 2. Examples of genetic diseases caused by single base substitution mutations.
Disease
Apert syndrome

mutation
1.5 x 10-5

“

basesubstitution
755C→G
758C→G
basesubstitution

Achondroplasia
“

1138G→A

Hemophilia

prevalence
1.5 x 10-5 b
to 6.25 x 10-6
“

0.5-1.5 x 10-6
“

Reference(s)_
Blank, 1960
Cohen et al., 1992

FGFR2

Glaser et al., 2003

to 6.25 x 10-6 b
1 x 10-6 b
(est.)
0.5-1.5 x 10-6 b
“

Mettler Fraser, 1999
FGFR3

Tiemann-Boege et al.,
2002

Factor VII Soucie et al., 1998
or IX
X –linked

7.7 x 10-6

3.85 x 10-6c

Factor IX Giannelli et al., 1992
X –linked

9 x 10-6 d
to 1.3 x 10-5 d

RB1

basesubstitution

Retinoblastoma

base4.35 x 10-5
substitution
to 6.25 x 10-5
(~45%) (live-births)

b

gene

2 x 10-4
2 x 10- 4 c
(live male births)

Hemophilia B

a

expecteda

Lohmann et al.,1996

expected frequency in sperm calculated from population prevalence and percent due to a paternal mutation
paternal genome represents 100% of the mutation incidence
6

_

table 2 (con't)
c
d

assumed ~50% mutation from paternal genome
based on 85% paternal (Dryja et al, 1997) for de novo mutations, and ~25% of prevalence due to de novo
mutations (Fitzgerald et al, 1983).
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The p53 protein promotes apoptosis in response to an accumulation of genetic errors,
thereby inhibiting the processes that may lead to neoplastic development (Hussain and Harris
1999; Martin et al., 2002). Somatic mutation of TP53 is a common occurrence in most human
cancers, with the vast majority of the mutations being (missense) single base-substitutions
(Hussain et al., 2003). A third of the mutations of the TP53 gene occur in “hotspot” codons such
as 175, 176, 245, 248, 249, 273, and 282 (Wilson et al., 2001; Olivier et al., 2003, Tapp et al.,
2007). Mutations in other tumor suppressor genes (APC, BRCA1, ATM, and RB1) are mostly
deletions or insertions (Hussain and Harris, 2006). These intragenic SBS mutations in the TP53
gene can lead to a change in one amino acid in the protein. Tumor derived p53 mutants
containing a point mutation within the DNA binding domain prevents, or in some cases alters,
the recognition of p53 binding sites (Yee and Vousden, 2005). Point mutations that prevent or
alter the binding sites could be described as “de-activating” the normal functions of the p53
protein. Yu et al., 1999, proposed that transcription activation by p53 is essential to its role as a
tumor suppressor. Recent studies have suggested that the TP53 mutation may act as an oncogene
or displaying gain of oncogenic function by altering the expression of associated proteins
(Glazko et al., 2006; Hussain and Harris, 2006). TP53 has been described as a “guardian of the
genome” (Lane, 1992) but if that role is mitigated by inheritance of a mutated copy, the resulting
effects are poorly understood.
Germline mutations of p53 have been identified in >70% of families with Li-Fraumeni
syndrome (LFS; MIM# 151623). Determining the frequency of TP3 mutations in human sperm
is crucial to understanding germline mutagenesis as it pertains to susceptibility to disease such as
in the Li-Fraumeni syndrome family, and elucidating roles in other diseases.

8

The RAS gene family (KRAS, NRAS, and HRAS) encodes highly conserved GTPbinding proteins and guanosine triphosphatases (GTPases).

Ras proteins act as molecule

switches, being active when it binds GTP and inactive when it binds GDP (De-Qing et al., 2004;
Potenza et al., 2005; Kratz et al., 2006). Activating mutations of the RAS genes cause the
protein to remain permanently in its active state, which in turn signals a number of effector
proteins that control many cellular pathways (e.g., transcription and proliferation). The majority
of the KRAS gene (MIM#190070) mutations found in codons 12, 13 and 61, are single base
substitutions which lead to the change of one amino acid in the protein (Bos et al., 1987; DeQing et al., 2004). The RAS genes are the most frequently activated oncogenic family in human
cancers (Bos, 1989). Kratz et al., 2006, observed that activating oncogenic mutations in the
HRAS gene affecting codons 12 or 13 are not detrimental to the developing embryo, when
present in the germline, whereas oncogenic KRAS mutations affecting these residues appear to
be embryonically lethal.

Although HRAS and KRAS are structurally similar, they perform

different roles during embryonic development and KRAS developmental functions cannot be
mitigated by the HRAS or NRAS (Koera et al., 1997; Kratz et al., 2006). This hypothesis is
supported by evidence in KRAS-deficient mice, in which the KRAS deficiency resulted in the
defect of myocardial cell proliferation and neuronal programmed cell death (Koera et al., 1997).
Determining the prevalence of Kras mutations in human sperm could suggest whether or
not this type of mutation is found in sufficient number to have the potential to be inherited, a lack
of individual with clinical evidence, or if the absent of viable offspring is due solely to the
suggested lethality in embryogenesis. The objectives of this study are to determine whether or
not SBS mutational frequencies in the TP53 and KRAS genes can be obtained from direct
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analysis of human semen specimens, and whether SBS mutational frequencies in sperm are
similar between activating (KRAS) and de-activating (TP53) mutations.
1.5 Disease Causing Mutations in the Human TP53 and Kristen-RAS (KRAS) Genes,
Somatic vs. Germline Mutations
Both somatic and germline DNA mutations have biological selection barriers for the
propagation and clonal expansion of genetic errors. For somatic mutations, selection may be
based on cell type and tissue specific functions as well as oncogenic processes.

Somatic

mutations in oncogenes and tumor suppressor genes are rare in normal tissue. TP53 gene
mutations are seen mostly in various types of cancers (e.g., head-neck, breast, lung, adenomas,
sarcoma, etc ((see http://p53.free.fr and www-p53.iarc.fr)), and in tissues exposed to mutagens or
carcinogen (i.e. lung cancers) (Soussi and Beroud, 2001; Hwang et al., 2003; Szymanska and
Hainaut, 2003; Glazko et al., 2006). Although Harvey-Ras and N-Ras gene mutations are found
in many cancers, mutations in the KRAS gene are typically found in carcinomas of the pancreas,
lung, colon, and thyroid (Andreyev et al., 1998 and 2001; De-Qing et al., 2004; Mascaux et al.,
2005).
Heritable germline mutations must be compatible with gamete functions, conception,
early cleavage, implantation, and embryonic and fetal development. Regardless of the type,
many mutations ranging from chromosomal aberrations to single base mutations may occur in
somatic cells but remain exceedingly rare simply because they do not provide for or enhance cell
division and clonal expansion of the new genotype. However, any mutation in gametes that does
not terminally interfere with reproductive and developmental processes is freely propagated and
present in every cell of the offspring. Understanding the risk of disease due to DNA mutation
induction in humans requires clarification of the occurrence and frequencies of mutations and
mutation spectra in somatic tissues and gametes. Over the last few decades, a lot of information
10

has been published on this subject associated with somatic diseases. Unfortunately, mutation
spectra and frequencies in the germline have not received the same degree of attention.
Germline mutations in TP53 are identified in 70% of families with Li–Fraumeni
syndrome (LFS; MIM# 151623), and 20%-30% of Li-Fraumeni-like (LFL) syndrome (Olivier et
al., 2002; Wu et al., 2006). The LFS syndrome displays dominant inheritance and confers
susceptibility to breast carcinoma, soft tissue sarcoma, brain tumors, osteosarcoma, leukemia,
and adrenocortical cancers (Hisada et al., 1998).
Recently, germline mutations in the KRAS gene were discovered in patients with Noonan
and cardio-facio-cutaneous (CFC) syndromes (Kratz et al., 2006).

These syndromes are

characterized by short, distinct facial anomalies, heart defects, and other abnormalities.
Moreover, it has been suggested that these particular mutations (V14I and T58I) demonstrated
unique aspect in the KRAS protein function that offers an explanation as to why the affected
individuals survived during embryonic development (Kratz et al., 2006). It must be noted that
these mutations are adjacent to, but not the typically altered amino acids residues in most cancers
relating to this gene, such as codons 12, 13, and 61.
The present work focuses on heritable and nonheritable gene mutations in human sperm.
As has been discussed, there are inherent differences in the mutational spectrum, mode, action,
and severity of effects in various tissues. Therefore we hypothesize that there are differential
patterns of mutational frequencies, and spectra of mutations in both TP53 and KRAS genes that
will be present in human sperm. To test this hypothesis I examined five loci, four codons in the
TP53 and one codon in the KRAS genes, to determine whether or not SBS mutational
frequencies in the TP53 and KRAS genes can be obtained from direct analysis of human semen
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specimens. Additionally, I hope to determine whether or not SBS mutational frequencies in
sperm are similar between activating (KRAS) and de-activating (TP53) mutations.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
The Taq polymerase (Amplitaq Gold) was purchased from Applied Biosystems (Foster
City, CA). Msp1, Hph1, and BsaA1 restriction endonucleases, Taq DNA Ligase for the LCR
amplification, and T4 polynucleotide kinase for end-labeling, were purchased from New England
Biolabs (Beverly, MA). [γ- 32P] ATP Redivue was purchased from Amersham/GE Healthcare
Corporation (Arlington Heights, IL).

Oligonucleotide primers were purchased as custom

synthesis from BioServe Biotechnologies Ltd (Laurel, MD).
2.2 Human Semen Specimens
In collaboration with Dr. Andrew Carlson (Albany Medical College), human semen
specimens (n=11) were obtained from consenting volunteers.

No personal information,

including age of the donor, was available due to the format of the consent forms and guidelines
of Institutional Review Board. The specimens were completely anonymous. This study was
approved by the Human Subjects Institution Review Boards of Albany Medical College (Albany,
NY) and Louisiana State University (Baton Rouge, LA). Samples were frozen and kept at -80°C
until DNA isolation was performed. In this study, eleven individuals’ samples were analyzed for
the presence of single base substitution mutations at five different codons in two genes.
2.3 DNA Isolation
All sperm DNA’s were isolated after a preparatory step to ensure the removal of superfluous
materials (i.e. proteins, RNA’s, somatic DNA’s, etc). Briefly, samples were transferred to 1.5ml
tubes centrifuged at 4,000 rpm for 15-20 minutes in an Eppendorf centrifuge. The suspension
was mixed with 20 µl of 0.02% periodic acid solution, vortex and centrifuged to ensure sample
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was at the bottom of the tubes. The samples were kept at room temperature for 15-20 minutes
then 400 µl grinding buffer was added. The samples were pelleted by centrifuged for 10
minutes, and then the solution was decanted and suspended in 50 µl hyaluronidase solution,
vortexed, centrifuged and incubated at 37oC for 1-1.5 hours. The samples were suspended in 50
µl collagenase/dispase/ringers solution and 5 µl DNase (2 units per µl), vortexed, centrifuged
and incubated at 37oC for 1-1.5 hours.

The samples were decanted, then suspended in 500 µl

grinding buffer, lysing buffer, and a final incubation in the presence of 20 µl 6.7% βmercaptoethanol solution (34µM final concentration) to crack the spermatozoa capsule (Clark
and Wilson; unpublished protocols). The vortexed, centrifuged and decanted DNA was isolated
with a standard proteinase K, chloroform/phenol extraction followed by ethanol precipitation
(Wilson et al., 2001; Tapp et al., 2007).

DNA concentration was measured on a

spectrophotometer with ratio 260/280 nm from 1.50 to 1.95. In case the ratio was not within the
specified range, re-isolation of the DNA was repeated until the DNA 260/280 nm ratio was
within the range of 1.5 to 1.95.
2.4 Multiplex –PCR/ RE/LCR Analysis
Tables 3 thru 6, contains the primer sequences, annealing temperatures, and product sizes of
the polymerase chain reaction (PCR)/ restriction-endonuclease digestion (RE)/ Ligase chain
reaction (LCR) selection and detection procedure for each specified gene site, which have been
reported by Wilson et al., 1999, 2000;Tapp et al., 2007. Figure 1, contains a flow chart of the
PCR and restriction endonuclease selection. The following is a brief summary of this method;
sperm DNA samples were subjected to a multiplex mutant enrichment protocol in which three
PCR amplification steps and two wild-type specific RE digestion steps were performed followed
by LCR for mutation detection and identification. The PCR reactions were standardized on
14

Applied Biosystems 9700 Thermal-Cycler (Foster City, CA), in a total reaction volume of 50µl,
containing 2.5

U AmpliTaq Gold, with supplied buffer, 1.7mM MgCl2, 200mM

deoxynucleoside triphosphates, and 1 mM of each PCR primer (Table 3).

Restriction

endonuclease digestion were performed on the PCR product (>5 hours) using Msp1 (> 10U/20µl
reaction) and BsaA1 (> 10U/20µl reaction) for codons 248 and 273, respectively, and Hph1 (>
10U/20µl reaction) for codon 12 of the KRAS gene (Table 4). The third PCR product from the
PCR/RE selection was analyzed for base substitution mutations using site-specific LCR designs.
A 30-cycle LCR amplification was then performed using 1µl of the final PCR/RE selection
product as template. The LCR amplifications were performed with 10 µl reactions containing ~
500,000 c.p.m. of 5’

32

P end-labeled invariant primers, 1 µm of each wild-type or mutant

discriminating primer (Tables 5 and 6), 4 µg sheared Salmon sperm DNA, and 15 U Taq Ligase
(New England Biolabs, Beverly, MA) in prepared LCR Buffer (20mM Tris-Hcl (pH) 7.6),
100mM KCL, 10 mM MgCl2, 1mM EDTA, 10 mM dithiothreitol, 1mM NAD+, and 0.1% Triton
X-100) (Tapp et al., 2007). The prevalence of mutant cells (number of mutants per wild-type
cells) in each sperm sample was determined by PCR/RE selection and LCR analyses utilizing
decreasing quantities of sperm DNA. Beginning with 6 µg and decreasing to 3, 0.6, and 0.3 µg
DNA, and 0 µg (no template control) the detection of mutant in these titrations represents a
prevalence of 1 x 10-6 (6µg), 2 x 10-6, 1 x 10-5, and 2 x 10-5, respectively. Human tumor cell lines
SW837 (CCL-235), A549 (CCL-185), Calu 1 (HTB-54), LS180 (CL-187), and SW480 (CCL228) were obtained from the American Type Tissue Culture (Rockville, MD) and grown as
recommended for use as mutant DNA standards according to their known mutations. Isolated
genomic DNA from cell line H157 was provided by BioServe Biotechnologies Ltd (Laurel,
MD).
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Table 3. PCR and Oligonucleotide template standards for PCR/RE/LCR analyses.
PCR
Sequence (5’ to 3’)
Primers
Hp53 exon 7
E7A
AGGCGCACTGGCCTCATCTTG
E7F
GACTGTACCACCATCCATACAA
E7GR
GGCAAGTGTCTCCTGACCTG
E7RB
GTGTGCAGGGTGGCAAGTGTC
Hp53 exon 8 & 9
E8BsaA1
ATCGTGAGCAGGGTAGAGGTAGAGCGACGAACAGCTT
TGAGGTA
E8SR
GGGCAGCTCGTGGTGAGG
E8R
TGGTCTCCTCCACCGCTTCTTG
E8S
GTGAGCAGGGTAGAGGAGAGCG
HKRAS exon 1 codon 12 site 1 and site 2
E1A
TTGCATTATTTTTATTATAAGGGCGGCTGAAAATG
E1G
GGAGTATTTGATAGTGTATTAACCTTATGTGTGACATG
12HphlR4 CAAAATGATTCTGAATTACGAGTCAACGAGCAGCACTC
TTGCCTACGT
E1FR2
GATTCTGAATTACGAGTCAACGAGCAG
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Size
21mer
22mer
20mer
21mer
44mer
18mer
22mer
22mer
35mer
38mer
48mer
27mer

Figure 1. Flow chart of PCR and Restriction Endonuclease Selection.
Modified from Wilson et al., 2001
Table 4. PCR primers, Restriction Endonucleases, and Annealing Temperatures.
PCR Primers sets and
Annealing PCR Product size (bp)
Restriction Endonucleases
Temp
PCR #1 Msp1, BsaA1 and Hph 1 60
Hp53E7 - Hp53E7R
66
237 bp
Hp53E8BsaA1 - Hp53E8R
60
184 bp
HKrasE1A - HKRAS12HphlR4
60
172 bp
PCR #2 A
Msp1 (only)
65
Hp53E7A - Hp53E7RB
66
178 bp
Hp53E8S – Hp53E8R
65
181 bp
PCR #2 B
BsaA1 and Hph 1 65
Hp53E8S – Hp53E8R
65
181 bp
HKRASE1A – HKRASE1FR2
66
166 bp
PCR #3 A
Msp1 (only)
60
Hp53E7F – Hp53E7GR
60
118 bp
Hp53E8S – Hp53E8SR
65
126 bp
PCR #3 B
BsaA1 and Hph 1 60
Hp53E8S– Hp53E8SR
65
126 bp
HKRASE1G – HKRASE1FR2
60
111 bp
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Table 5. LCR Primers for TP53 codons 248, 282, and 273 site 1.
LCR Primers
Sequence (5’ to 3’)
L2 Hp53c248s1
GGAGGCCCATCCTCACCATC
LR2 Hp53c248s1
GTTCATGCCGCCCATGCAGG
MtHp53c248s1 GL
AAAAAAAAATGGGCGGCATGAACG
MtHp53c248s1 AL
AAAAAAATGGGCGGCATGAACA
MtHp53c248s1 TL
AAAAATGGGCGGCATGAACT
WtHp53c248s1 L
AAATGGGCGGCATGAACC
MtHp53c248s1 GLR AAAAAAAGAGGATGGGCCTCCC
MtHp53c248s1 ALR AAAAAGAGGATGGGCCTCCT
MtHp53c248s1 TLR AAAGAGGATGGGCCTCCA
WtHp53c248s1 LR
AGAGGATGGGCCTCCG
L2 Hp53c282s1
GGGGCGAACAGAGGAAGAGAATCTCCG
LR Hp53c282s1
CACAAACACGGACAGGACCCTCTCTG
MtHp53c282s1 GL
AAAAAAAAAACTGTCCTGGGAGACGACG
MtHp53c282s1 AL
AAAAAAAACTGTCCTGGGAGACGACA
MtHp53c282s1 TL
AAAAAACTGTCCTGGGAGACGACT
WtHp53c282s1 L
AAAACTGTCCTGGGAGACGACC
MtHp53c282s1 CL2 GCCCGCTTGTCTCCTTCTCTATATTA
MtHp53c282s1 TL2
ACCGCTTGTCTCCTTCTCTTATTA
MtHp53c282s1 AL2 TCCGCTTGTCTCCTTCTCATAT
WtHp53c282s1 LR2 GCCGCTTGTCTCCTTCTCTT
L Hp53c273s1
GTGTTTGTGCCTGTCCTGGGAGAGA
LR Hp53c273s1
CCATCTCGCTGCCTTGTCGAAACTCCAT
MtHp53c273s1 GL
AAAATAAGACGGAACAGCTTTGAGGTAG
MtHp53c273s1 AL
AATAAGACGGAACAGCTTTGAGGTAA
MtHp53c273s1 TL
TAAGACGGAACAGCTTTGAGGTAT
WtHp53c273s1 L
CGACGGAACAGCTTTGAGGTAC
WtHp53c273s1 LR
AAACAGGACAGGCACAAACACG
MtHp53c273s1 TLR AAAAACAGGACAGGCACAAACACA
MtHp53c273s1 ALR AAAAAACCAGGACAGGCACAAACACT
MtHp53c273s1 GLR AAAAAAAAACAGGACAGGCACAAACACC
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Size
20 mer
20 mer
24 mer
22 mer
20 mer
18 mer
22 mer
20 mer
18 mer
16 mer
27 mer
26 mer
28 mer
26 mer
24 mer
22 mer
26 mer
24 mer
22 mer
20 mer
25 mer
28 mer
28 mer
26 mer
24 mer
22 mer
22 mer
24 mer
26 mer
28 mer

Table 6. LCR Primers for TP53 codons 273 site 2 and KRAS codon 12 site 1.
LCR Primers
Sequence (5’ to 3’)
L Hp53c273s2
TGTTTGTGCCTGTCCTGGGAGAGAC
LR Hp53c273s2
CATCTCGCTGCCTTGTCGAAACTCCATG
MtHp53c273s2 CL
ATATACGACGGAACAGCTTTGAGGTACC
MtHp53c273s2 AL
ATAAATCGGAACAGCTTTGAGGTACA
MtHp53c273s2 TL
AAATCGGAACAGCTTTGAGGTACT
WtHp53c273s2 L
GACGGAACAGCTTTGAGGTACG
WtHp53c273s2 LR
AAACCAGGACAGGCACAAACAC
MtHp53c273s2 TLR AAAAACCAGGACAGGCACAAACAA
MtHp53c273s2 ALR AAAAAAACCAGGACAGGCACAAACAT
MtHp53c273s2 CLR AAAAAAAAACCAGGACAGGCACAAACAG
LR2 HKRASc12s1
GTGACGTAGGCAAGAGTGCAGGTC
MtHKrasc12s1CL
AAAAAAAAAAACTTGTGGTAGTTGGAGCTC
MtHKrasc12s1TL
AAAAAAAAACTTGTGGTAGTTGGAGCTT
MtHKrasc12s1AL
AAAAAAACTTGTGGTAGTTGGAGCTA
WtHKrasc12s1L
AAAAACTTGTGGTAGTTGGAGCTG
L3 HKRASc12s1
AGCTCCAACTACCACAAGTTTATATTCAGTC
A
WtHKrasc12s1LR2
CACTCTTGCCTACGTCACC
MtHKrasc12s1ALR2 AGCACTCTTGCCTACGTCACT
MtHKrasc12s1TLR2 AAAACACTCTTGCCTACGTCACA
MtHKrasc12s1CLR2 AAAAAACACTCTTGCCTACGTCACG
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Size
25 mer
28 mer
28 mer
26 mer
24 mer
22 mer
22 mer
24 mer
26 mer
28 mer
24 mer
30 mer
28 mer
26 mer
24 mer
32 mer
19 mer
21 mer
23 mer
25 mer

To demonstrate assay sensitivity at one in a million, control mixtures were prepared with
6 µg genomic DNA and 6 pg of genomic mutant (cell line) DNA. The purchased Human
Genomic DNA was checked for mutations at the base sites of interest at the 10-7 sensitivity
before use in these mutant standard mixtures to insure a negative background.
Significant differences between semen specimens (n =11) for mutation frequency and
prevalence were determined by a Chi-squared test for dichotomous variables and the t-test and
one-way analysis of variance (ANOVA) for continuous variables.

Correlations between

variables were assessed by pairwise covariance and linear regression methods. The statistical
package SPSS was used to perform these tests. Significance was set at P<0.05.
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CHAPTER 3
RESULTS AND DISCUSSION
3.1 General Results
Single-base substitution mutations were found in 13 of 55 (24%) base pair sites tested in
normal human sperm specimens; per semen specimen one or more mutations were identified in 8
of 11 (73%)(Table 7). Overall, TP53 codon 248 mutations (Figure 2) were more frequent (6/11,
55%) than KRAS codon 12 (4/11, 36 %). Five specimens were not analyzed for mutants in
TP53 codon 282 site 1 due to limited sample size and required quantities of DNA. In a previous
study, no mutations were observed in 19 specimens of peripheral blood leukocytes for codon 282
(Yin, Xiuquin and Wilson, VL, unpublished data). A representative autoradiograph of TP53
codon 282 site 1 is shown in Figure 3. Similarly, no mutations were observed in the eleven
semen specimens for TP53 codon 273 site 1 (Figure 4). In contrast, three (27%) of the semen
samples had mutants in TP53 codon 273 site 2 (Figure 5). Lastly, four of the eleven (36%)
semen specimens tested where positive for mutants in KRAS codon 12 site 1. Figure 6, is a
representative autoradiograph of KRAS codon 273 site 1.

Listed in order decreasing of

frequency: TP53 codon 248 site 1 (55 %), KRAS codon 12 site 1 (36%), TP53 codon 273 site 2
(27%), and both TP53 codon 273 site 1 and TP53 codon 282 site 1 (0%). A summation of the
specific mutation and frequency range (prevalence) found in eleven human semen specimens are
presented in Table 7.
There were significant differences in the frequency of mutations between the TP53 and
KRAS genes, specifically KRAS codon 12 site 1 compared to TP53 codon 282 site 1 and codon
273 site 1 (both were P< 0.04). In addition, there were highly significant differences found

21

within the TP53 gene, specifically TP53 codon 248 site 1 compared to TP53 codon 282 site 1
and TP53 codon 273 site 1 (both were P< 0.006).
Five samples (45%) harbored more than one mutation identified (all 5 specimens
harbored 2 single base pair mutations). Specimens S02-365, S03-401, S00-026, S03-241, and
S03-428 each contained two mutations out of five loci examined.

Three specimens harbored

only one mutation (S02-054, S03-401, and S03-050), and there were no detectable mutations in
three specimens (S01-010, S02-063, and S03-398). Overall, no significant differences in the
frequency of mutations were found between the eleven specimens (P< 0.49) (Table 7).

Base

pair transitions were the only type of mutation identified in this study (Table 7). TP53 codon
248 site 1 contained only C>T mutations, whereas both TP53 codon 273 site 2 and KRAS codon
12 site 1 contained only G>A mutations (Table 7). Table 8, contains a raw data comparison of
sperm, peripheral blood leukocytes (PBL) and adjacent normal vulvar skin. Similar base pair
transition C > T mutations, were observed in both PBL and adjacent normal vulvar skin. In
contrast, adjacent normal vulvar skin harbored both G > A, and G > C (transitions and
transversions) mutations in TP53 codon 273 site 2 and G > A, and G >T mutations in KRAS
codon 12 site 1 (Table 8). Interestingly, the SBS mutation frequencies of TP53 were found to be
higher in sperm than that previously reported for normal tissue (Table 8). This was due to the
elevated mutation frequency of the first base of codon 248 in sperm. The proportion of semen
specimens providing detectable C > T mutations in TP53 codon 248 was twice that reported for
circulating peripheral blood leukocytes (PBL) (Wilson et al., 2000), or normal skin (normal
vulvar skin and fore skin) specimens (Tapp et al., 2007), although the differences are not
significant (P> 0.17/0.41, respectively). The frequency of KRAS mutations detected in sperm
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samples was similar to that reported for normal adjacent skin, but higher than that reported for
normal skin without adjacent cancer.
3.2 Mutational Spectrum
The spectrum of SBS mutations found in this study of semen specimens was limited to
only transition mutations. A similar spectrum of SBS mutations, with the vast majority being C
> T or G > A transitions, causing human genetic disease has been described by Cooper and
Krawczak, 1990. It has been reported that a bias for transitions at CpG sites, such as those seen
in the first base in TP53 codons 248 and 273 site 1 and 2 (Magewu and Jones, 1994; Drost and
Lee, 1995; Tapp et al., 2007) may be the result of 5-methyldeoxycytidine deamination.
Oxidative processes may enhance 5- methyldeoxycytidine deamination, although this reaction
also occurs spontaneously (Magewu and Jones, 1994). Comparisons of the present work with
published studies are contained in Table 8.

The proportion of semen specimens proving

detectable C > T mutations in TP53 codon 248 was twice that reported for normal skin (normal
vulvar skin and foreskin) specimens (Tapp et al., 2007), or circulating peripheral blood
leukocytes (PBL) (Wilson et al., 2000), although the differences are not significant.

No

mutations were detected in sperm in the first base of codon 273 (Table 8), but this finding is
consistent with the rarity of mutations at this TP53 base site, as reported by Tapp et al., 2007, in
normal skin adjacent to squamous cell carcinoma.

In contrast to the present spectra results,

observations in vulvar skin specimens by Tapp et al., 2007, included G > C mutations in the
second base of codon 273, and G > T mutations in the first base of codon 12 of KRAS. G > A
transitions, were the only type of mutations observed in our study of the KRAS gene. G > A
transitions, which can occur due to bypass misreplication of unrepaired endogenously produced
O6 –methylguanine, are one of the most frequent point mutations for all human somatic missense
mutations (Stenson et al, 2003; Tapp et al 2007).
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Figure 2. Representative autoradiograph of TP53 codon 248 site 1 (specimen S00-026).
PCR blank: negative control during PCR/RE selection with no DNA template (water). LCR
blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of DNA
per specimen; 2x10-6: 3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x10-5:
0.3µg of DNA per specimen. Wt: LCR products from Wild–type DNA strands; A and G: one
pmol of each oligomeric standards mutant A and mutant G were included in these analyses as
positive mutation standard markers (see Table 5 for primer sequences). A standard 10-6 mixture
of genomic DNA from the SW837 cell line provided verification of the detection sensitivity of
the mutant T standard. Film was exposed for 1 hour. Reprinted by permission of John Wiley &
Sons, Inc.
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Figure 3. Representative autoradiograph of TP53 codon 282 site 1 (specimen S03-401).
PCR blank: negative control during PCR/RE selection with no DNA template (water). LCR
blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of DNA
per specimen; 2x10-6: 3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x10-5:
0.3µg of DNA per specimen. Wt: LCR products from Wild–type DNA strands; MtT, MtA, and
MtC: one pmol of each oligomeric standards mutant T, mutant A, and mutant C were included
in these analyses as positive mutation standard markers (see Table 5 for primer sequences). Film
was exposed for 1 hour.
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Figure 4. Representative autoradiograph of TP53 codon 273 site 1 (specimen S01-010).
PCR blank: negative control during PCR/RE selection with no DNA template (water). LCR
blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of DNA
per specimen; 2x10-6: 3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x10-5:
0.3µg of DNA per specimen. Wt: LCR products from Wild–type DNA strands; MtT, MtA, and
MtC: one pmol of each oligomeric standards mutant T, mutant A, and mutant C were included
in these analyses as positive mutation standard markers (see Table 5 for primer sequences).
Film was exposed for 1 hour.
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Figure 5. Representative autoradiograph of TP53 codon 273 site 2 (specimen S03-241).
PCR blank: negative control during PCR/RE selection with no DNA template (water). LCR
blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of DNA
per specimen; 2x10-6: 3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x10-5:
0.3µg of DNA per specimen. Wt: LCR products from Wild–type DNA strands; MtT, and MtC:
one pmol of each oligomeric standards mutant T, and mutant C were included in these analyses
as positive mutation standard markers (see Table 6 for primer sequences). A standard 10-6
mixture of genomic DNA from the SW480 cell line provided verification of the detection
sensitivity of the mutant A standard. Film was exposed for 1 hour.
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Figure 6. Representative autoradiograph of Human KRAS codon 12 site 1 (specimen S03-050).
LCR blank; negative control during LCR reaction with no DNA template (water). 10-6: 6µg of
DNA per specimen; 2x10-6: 3µg of DNA per specimen; 10-5: 0.6µg of DNA per specimen; 2x105
: 0.3µg of DNA per specimen. Wt: LCR products from Wild–type DNA strands (see Table 6
for primer sequences). A standard 10-6 mixture of genomic DNA from the A549 cell line
provided verification of the detection sensitivity of the mutant A standard. Film was exposed for
1 hour. Reprinted by permission of John Wiley & Sons, Inc.
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Table 7. Frequency and prevalence of rare single base mutations in human sperm. a
Specimen
S00-026

TP53 c248s1b
Prev
1.0E-6

S01-010
S02-054

1.0E-5

S02-063
S02-365

1.0E-5

S03-050
S03-241

1.0E-5

S03-398
S03-401

1.0E-5

S03-402
S03-428

1.0E-5

TP53 c273s1
base

Prev

TP53 c273s2 KRAS c12s1
base

Prev base

Prev base

T

Wt

Wt

Wt

Wt

Wt

Wt

T

Wt

Wt

Wt

Wt

Wt

Wt

Wt

T

Wt

Wt

1.0E-6 A

Wt

Wt

Wt

1.0E-5 A

T

Wt

Wt

Wt

Wt

T

Wt

Wt

Wt

Wt

1.0E-6 A

Wt

T

Wt

1.0E-6 A

Wt

1.0E-6 A

a

1.0E-6 A

Wt
Wt
1.0E-5 A

Prevalence is denoted as mutations per 106 genomes, which is equivalent to mutations per 106 sperm.
b
Base sites are denoted by gene, codon (c), and first (s1) or second (s2) base in codon.
Wt: wild type codon.
c
Reprinted by permission of John Wiley & Sons, Inc.
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Table 8. Comparison of frequencies of rare single base mutations sperm and normal somatic cells.
Sperm

Circulating
Leukocytes

Normal skin, no
a

cancer

b

Normal Skin,
adjacent cancer

P value

c

b

Mutants/all sites tested

13/44 (30%)

17/66 (26%)

5/45 (11%)

20/88 (23%)

0.83/0.06 /0.52

+ mutation/specimen

8/11 (73%)

8/19 (42%)

5/13 (38%)

14/22 (64%)

0.21/0.20/0.90

1 mutation/specimen

3/11 (27%)

2/19 (11%)

5/13 (38%)

10/22 (45%)

0.50/0.88/0.53

2 mutations/specimen

5/11 (45%)

3/19 (16%)

3/22 (14%)

0.18/

2/19 (11%)

1/22 (4%)

>2 mutations/specimen
d

Prevalence

6

~ 0.7 mt / 106 wt

>1 mt / 10 wt
genomes

genomes
6

Mean±sd

5±1 mt / 106 wt

6±5 mt / 10 wt
genomes

21 mt / 106 wt

20 mt / 10 wt
genomes

genomes
6

Median

1 mt / 106 wt

5 mt / 10 wt
genomes
e

0.34

genomes
6

Maximum

/0.11

0.10

genomes

4/11 (36%)

3/21 (14%)

11/36 (31%)

0.32/1.0

G34A

4/11 (36%)

2/12 (17%)

9/21 (42%)

0.55/0.97

G34T

0/11

1/12 (8%)

1 (5%)

G35A

0/11

0/9

1/15 (7%)

TP53 c248 & c273

9/33 (27%)

2/24 (8%)

9/52 (17%)

0.15/0.54

KRAS c12

TP53 c248

f

C742T
TP53 c273
C817T

g

6/11 (55%)

5/18 (28%)

2/15 (13%)

4/18 (22%)

0.30/0.07 /0.17

6/11 (55%)

4/18 (22%)

2/8 (25%)

4/18 (22%)

0.17/0.41/0.17

0/9

5/34 (15%)

0.62/0.78

1/17 (6%)

0.82

3/22 (14%)
0/11
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(Table 8 cont.)
G818A

3/11 (27%)

0/9

2/17 (12%)

0.28/0.59

G818C

0/11

0/9

2/17 (12%)

0.67

C→T

6/22 (27%)

4/18 (22%)

2/8 (25%)

5/35 (14%)

1.0/0.73/0.39

G→A

7/22 (32%)

1/48 (2%)

2/37 (5%)

12/53 (23%)

0.001/0.02/0.81

G→C

0/22

0/53

0/37

2/53 (4%)

0.89

G→T

0/22

11/48 (23%)

1/37 (3%)

1/53 (2%)

0.04/0.79/0.65

Bold: significant difference at P<0.05. Italics weak significance P< 0.1. bp: base pair. mt: mutant cells. NS: not significant.
sd: standard deviation. Wt: wild type cells.
a
summary of data reported by Wilson et al.((Wilson et al. 2000)).
b
summary of data reported by Tapp et al.((Tapp et al. 2007))
c
comparisons between groups - sperm vs. circulating leukocytes (PBL) / sperm vs. normal skin, no cancer / sperm vs. Normal skin
with adjacent cancer. Statistical analyses is based on Chi squared analyses with the Yates’ Correction where needed.
d
prevalence: mutant cells per 106 wild type genomes, which is equivalent to mutations per 106 haploid sperm or 0.5 x 106 diploid
somatic cells.
e
KRAS c12, G34C and G35C or T mutations were not detected.
f
TP53 c248, C742A or G mutations were not detected.
g
TP53 c273, C817A or G and G818T mutations were not detected.
h
Reprinted by permission of John Wiley & Sons, Inc.
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Transition mutations have been reported in CpG sites in other tissues and in SBS
diseases, such as peripheral blood leukocytes (PBL), normal skin, achondroplasia, and
vulvar lichen sclerosus (Wilson et al., 2000; Tiemann-Boege et al., 2002; Tapp et al.,
2007). The precise mechanism and the reason(s) for this apparent bias are unknown at
this time. In somatic tissues, oxidative damage has been suggested as a mechanism for
the production of transition mutations, but the absence of actively inflamed mucosa
and/or absorption of UV radiation severely limit these as causal factors of mutations in
sperm.

There is a remote possibility that UV radiation may play a role in the

development of some oxidative damage during spermatogenesis, which further
demonstrates the need for more empirical data in this area. Interestingly, previous reports
utilizing semen specimens observed only transition mutations at a CpG dinucleotide site,
which as mentioned above are susceptible to spontaneous deamination (Tiemann-Boege
et al., 2002).
3.3 Mutational Frequencies and Prevalence
Drost and Lee, 1995 proposed that the enzymes involved in repair and control of
replication fidelity operate at activities within the germ cells which would deliver null
mutation rates at the gene level between ~10-5 to 10-6 per generation. The background
frequency of mutations found herein were in the range of 1 x 10-6 to 2 x 10-5 mutant
sperm per total spermatozoa sampled for both TP53 and KRAS genes, which are similar
to previous observations of the frequency of SBS mutations of the FGFR2 and FGFR3
genes in human sperm (Tiemann-Boege et al., 2002 and Glaser et al., 2003) (Table 2).
Interestingly, the prevalence/ frequency reported by Tiemann-Boege et al., 2002 and
Glaser et al., 2003, were seen as relatively high as compared to other diseases (Table 2),
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but the present study demonstrates a consistent mutational load of normal human sperm,
which suggest a more general occurrence of these frequencies in normal semen
specimens. In this study, 73% (8/11) of the semen specimens contained detectable
mutants in the five base sites tested (Table 8). This mutation frequency is higher than
that observed in PBL (8/19, 42%), PBL (8/19, 42%), normal skin (5/13, 38%), and
adjacent normal vulvar skin (14/22, 64%), although the base sites studied vary in the PBL
analyses (Table 8). Interestingly, these results suggest that a percentage of normal
individuals may be reservoirs of a significant frequency of oncogenic mutations.
The prevalence and frequency of SBS mutations in the KRAS and TP53 genes
observed in this study are unique; this work represents the first report of SBS frequencies
of TP53 and KRAS gene mutations in normal human semen specimens. KRAS gene
mutations were present in normal semen specimens at a frequency that would not be
expected from the lack of incidence of genetic disease that would result from the
constitutional inheritance of these mutations. In fact, oncogenically activating codon 12
mutations have not been reported at the constitutional level in any human. Results of this
study compared with previous studies (Table 8) suggest that oncogenic mutations are
present in both sperm and somatic tissues at similar frequencies. The presence of rare
oncogenic mutations in somatic disease may lead to cancer, while the presence of sperm
harboring these same gene mutations has the potential to give rise to individuals
harboring this error constitutionally. Fortunately, human constitutional KRAS codon 12
mutations have not been found and carriers of TP53 mutations, i.e. Li-Fraumeni cancer
family syndrome carriers, are rare (Olivier et al., 2003; Wu et al., 2006). This contrast
between the expected and the observed frequencies of mutations in the KRAS and TP53
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genes suggests that selection against these types of mutations must be in fertilization,
early cleavage, or embryogenesis. Again, based on the incidence of disease in the
population, selection seems to be more negatively biased against KRAS than TP53 gene
mutations. Selection biased against particular mutations in sperm has been reported for
Apert syndrome. Two different mutations in the fibroblast growth factor receptor 2
(FGFR 2) gene codon 755 C >G and codon 758 C >G, can result in Apert syndrome with
a higher incidence of Apert seen with the codon 755 mutation (Glaser et al., 2003).
Directly assaying sperm as demonstrated in this study has the potential to answer
questions that have lingered for decades, such as the impacts of paternal age (Drost &
Lee, 1995; Crow, 1993; 1996; 2000; Wyrobek et al., 2006), and gonadal mosaicism
(Selby, 1998) on hereditary risk estimation, origin of hereditary diseases, and evolution.
A more precise understanding of the different mechanisms governing which mutations
are selected for or against inheritance in offspring can be garnered as more loci in sperm
are studied.
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CHAPTER 4
CONCLUDING REMARKS
The direct analysis of semen specimens presented in this study provides new
insight into the prevalence and heritability of mutations in the human germline.
Interestingly, in these specimens both TP53 and KRAS genes contained frequencies of
only transitional mutations.

The cause of this bias observed within the mutational

spectrum is unknown and awaits further investigation. This is the first study to report
SBS mutations and frequencies in TP53 and Kristen-Ras codon 12 gene in normal human
sperm. The KRAS gene is frequently mutated in somatic disease (i.e. cancers), but a lack
of reports of constitutional KRAS codons 12,13 or 61 mutations suggest that this
particular mutation is selected against during the processes of fertilization, early
cleavage, or embryogenesis.
The direct examination of sperm has potential applications in diagnostics and
assessment of disease, such as development of improved risk evaluation, clinical
treatment protocols, and genetic counseling. Development of assays and protocols to
directly evaluate SBS mutations in sperm, in addition to the standard testing of specimens
such as blood and stool, could lead to higher levels of holistic safety in industries where
workers are continually exposed to environmental mutagenic hazards.

Treatment

protocols are increasingly being tailored to individual needs based on available data. As
mentioned above, semen specimens can be added to the collection of information
gathered about the individual, which could address concerns regarding gamete mosaicism
especially for specific disease causing mutations, and the risks to future offspring
following prolonged radiation or chemotherapy for the treatment of cancer. Lastly,
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genetic counseling would benefit from the ability to establish baselines in an individual’s
semen and monitor changes during intervals of time to improve risk assessment given to
couples concerned with heritable diseases.
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